Other Liabilities

Other liabilities comprised the following:

Other Liabilities

 

 

Dec. 31, 2017

 

Dec. 31, 2018

 

 

Total

 

Of which current

 

Total

 

Of which current

 

 

€ million

 

€ million

 

€ million

 

€ million

Other tax liabilities

 

420

 

418

 

654

 

653

Deferred income

 

1,156

 

195

 

65

 

19

Liabilities to employees

 

181

 

164

 

252

 

231

Liabilities for social expenses

 

138

 

130

 

141

 

136

Accrued interest on liabilities

 

149

 

139

 

268

 

257

Liabilities from derivatives

 

321

 

306

 

327

 

165

Miscellaneous liabilities

 

403

 

300

 

764

 

661

Total

 

2,768

 

1,652

 

2,471

 

2,122

The deferred income included €30 million (2017: €48 million) in grants and subsidies received from governments, of which €3 million (2017: €17 million) was reversed through profit or loss.

Other miscellaneous liabilities included financing commitments of US$141 million (2017: US$195 million) for the joint venture Casebia Therapeutics LLP, United Kingdom, established in December 2015 with CRISPR Therapeutics AG, Switzerland, and a further financing commitment of US$60 million (2017: US$70 million) for the joint venture Joyn Bio LLC, United States, established in September 2017 with Ginkgo Bioworks, Inc., United States, which will operate in the area of the plant microbiome.

Compare to Last Year